Table 5.

HIV-1-Neutralizing Activity in Plasma and CVL

	Laboratory A		Laboratory E			Laboratory F
	NL4.3		CC.1		NL4.3	JRCSF	SF162		aMLV
	Plasma	CVL	Plasma	CVL	Plasma	Plasma	Plasma	CVL	Plasma	CVL
HIV-1 infected subjects
1	1,000	12	<60	–	2,586	87	5,846	<10	2,586	<10
2	1,620	12	<60	–	7,271	96	25,870	24	<20	<10
3	540	–	<60	–	2,442	807	19,884	<10	23	<10
4	540	–	<60	–	1,683	50	2,549	<10	25	<10
5	120	–	<60	>17.1	562	84	5,155	13	20	<10
6	540	–	<60	–	2,113	656	5,479	<10	278	<10
7	180	nd	<60	14.3	1,334	400	10,474	<10	25	<10
8	1,000	–	<60	–	3,805	141	22,693	22	54	18
9	180	–	<60	nd	966	53	4,891	43	29	<10
10	180	–	<60	–	545	82	3,709	<10	<20	<10
11	360	nd	<60	–	662	140	1,045	<10	<20	<10
12	180	–	<60	–	638	443	1,100	13	23	<10
13	180	–	<60	–	179	157	1,343	<10	26	<10
14	300	–	<60	–	794	33	737	51	30	25
15	180	–	111.2	–	477	82	12,790	<10	36	<10
16	60	–	<60	–	474	41	2,236	39	22	<10
17	180	54	<60	>17.1	1,056	108	9,851	<10	<20	<10
18	60	–	<60	>17.1	532	58	2,282	<10	32	<10
19	180	–	80.0	–	1,846	675	4,304	30	367	<10
20	180	–	<60	–	1,135	45	11,213	<10	<20	<10
21	180	–	<60	–	507	79	568	<10	<20	<10
22	1,000	–	<60	–	7,270	190	8,292	<10	29	<10
23	180	–	<60	–	819	644	2,994	<10	22	<10
24	60	–	126.8	–	315	58	1,750	<10	<20	<10
25	500	–	<60	10.0	1,126	207	8,434	17	<20	<10
26	500	–	<60	–	1,161	435	2,605	28	32	<10
HEPSN subjects
1	–	–	<60	–	38	41	30	290	28	<10
2	–	–	<60	–	29	23	37	<10	30	<10
3	–	–	<60	nd	33	23	25	92	<20	<10
4	–	–	<60	–	48	33	35	<10	36	<10
5	–	–	<60	–	31	<20	73	<10	21	<10
6	–	–	<60	–	47	26	31	12	30	<10
7	–	–	<60	nd	22	<20	22	<10	<20	<10
8	–	–	<60	–	40	24	22	<10	<20	<10
9	–	–	<60	–	27	22	20	<10	21	<10
10	60	nd	<60	>17.1	32	27	23	<10	<20	<10
11	60	–	<60	–	21	30	29	13	21	<10
12	60	–	<60	–	28	<20	23	<10	<20	<10
13	–	–	<60	–	34	<20	24	<10	28	<10
14	–	–	<60	–	28	24	39	16	23	<10
15	–	–	<60	–	38	26	33	63	34	<10
16	–	–	<60	–	<20	<20	30	<10	30	<10
17	–	–	<60	–	23	21	34	13	30	<10
18	–	–	<60	–	<20	<20	<20	<10	<20	<10
19	–	–	<60	>17.1	42	31	32	17	28	<10
20	–	–	<60	>17.1	35	<20	21	<10	30	<10
21	–	–	<60	–	<20	<20	22	11	<20	<10
22	–	–	<60	–	21	22	<20	<10	<20	<10
23	–	–	<60	–	<20	<20	<20	<10	<20	<10
24	–	–	<60	–	<20	<20	22	11	<20	<10
25	–	–	<60	–	41	27	24	<10	33	<10
26	–	–	<60	–	27	<20	32	<10	26	<10
27	–	–	<60	–	26	22	32	75	26	<10
28	–	–	<60	–	287	136	696	31	23	11
29	–	–	<60	–	27	21	<20	42	22	<10
30	–	–	<60	–	26	23	27	<10	20	<10
31	–	–	<60	–	36	23	24	11	27	<10
32	–	–	<60	–	<20	<20	23	20	<20	<10
33	–	–	<60	–	25	23	24	<10	<20	<10
34	–	–	<60	–	27	<20	27	<10	<20	<10
35	–	–	<60	–	28	<20	21	<10	<20	<10
36	–	–	<60	–	63	65	62	33	36	<10
37	–	–	<60	–	20	21	22	12	<20	<10
38	–	–	<60	–	29	24	29	15	27	<10
39	60	–	<60	–	29	33	36	13	23	<10
40	–	–	<60	–	30	26	28	<10	31	<10
41	–	–	<60	–	<20	<20	<20	11	<20	<10

The values shown represent the last reciprocal dilution that inhibited viral infection by 50% as described for each laboratory in the Materials and Methods. Dashes denote samples which failed to neutralize virus. nd: not done.